Photodynamic therapy for age-related macular degeneration: a candid appraisal

The high persistence/recurrence rate is also problematic: patients need to return for multiple repeat treatments, despite them not perceiving any obvious benefit. Because Medicare or private insurance often covers only a percentage of the drug and treatment charges, patients often are left with considerable personal costs, particularly in cases requiring multiple treatments and for off-label treatment of occult lesions. [...]there is currently considerable interest in exploring other treatments for choroidal neovascularization.